- German Social Democrat-led coalition expected to liberalize medical cannabis market
- Analysts predict over one million medical cannabis patients in Germany by 2024, market estimated to reach $8.9 billion by 2028
- RYAH entered German market via observational study with Four 20 Pharma GmbH
- RYAH provides IoT product ecosystem of volume-control devices, medicine-carrying components, mobile applications
- RYAH ecosystem offers reliable way for researchers and clinicians to develop well-controlled research environments
Germany’s recent 2021 election is expected to result in a new political environment via a coalition containing cannabis-positive political factions that aim to liberalize the country’s plant-based medicine market (https://cnw.fm/z1BxY). RYAH Group (CSE: RYAH), the leader in volume-control technology for plant-based medicine, is already on track to penetrate the German market with a strategic partnership aiming to catalyze the company’s mission of providing remote-health solutions and analytics-based patient treatments to the world.
Germany’s winning party – the Social Democrats – are currently in talks with the Greens and Free Democratic Party to form a coalition to replace Angela Merkel’s current government. A pre-election analysis by Volt Face revealed that the Social Democrats “can generally be considered pro-cannabis policy reform,” with even greater pro-cannabis sentiment among the other members of the proposed coalition (https://cnw.fm/ocpHq).
Though access to cannabis in Germany may be limited, the current system appears to be serving as a model for the rest of the European Union through policies that demonstrate a controlled, prescribed, and relatively efficient medical cannabis market (https://cnw.fm/qltht). Recent reports by the Prohibition Partners organization, based on translated publications from the German Bundestag, provided positive insights into the German medical cannabis model and possible implications for the rest of the European Union.
According to the report, there are slightly more than 13,000 complete patient records from roughly 128,000 patients receiving medical cannabis in the country. Market analysts predict one million medical cannabis patients in Germany by 2024 with a total market value of $8.9 billion by 2028, making it one of “the world’s most valuable medical cannabis markets,” according to the New Frontier Data organization.
“Germany represents one of the most important and influential plant-based medicine markets in Europe, and we are thrilled to be initiating a pilot program with Four 20 Pharma GmbH in the region,” said Gregory Wagner, RYAH Group CEO. “Four 20 has a strong network of doctors and patient care facilities, making it an excellent partner to pilot RYAH’s smart inhaler and proprietary data analytics as the industry moves towards perfecting prescribing practices and patient regimens.”
RYAH provides an ecosystem of IoT products that include volume-control devices, medicine-carrying components, and mobile applications. Used together, they can provide a reliable way for researchers and clinicians to develop well-controlled environments to study the use of cannabis for chronic medical conditions and palliative care. Along with treatment administration, RYAH’s infrastructure aims to generate AI-powered models that can provide precision treatments for various diseases.
RYAH is dedicated to leveraging technological innovation that unlocks the power of data to provide better patient outcomes. The company’s robust intellectual property portfolio, comprised of AI-powered technology and portable, cost-effective products, is positioning the company to capture and capitalize on growth opportunities in Germany, the European Union, and beyond.
For more information, visit the company’s website at www.RYAHGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://cnw.fm/RYAH
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
